相关实验视频

Updated: Jun 13, 2025

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

脂蛋白A-IV通过增强活性蛋白C来调节凝血和缺血性中风

Musan Yan¹, Yuewei Wang², Liyuan Niu²

¹School of Basic Medicine, Qingdao University, Qingdao 266071, Shandong, China.

Journal of thrombosis and haemostasis : JTH

|June 11, 2025

概括

脂蛋白A-IV (ApoA-IV) 通过增强活性蛋白C (APC) 活性来调节血液凝固,为抗血栓治疗提供了新的途径. 较低的ApoA-IV水平与血栓形成风险的增加有关.

科学领域:

生物化学和分子生物学
血液学和血栓症研究研究
炎症和脂质新陈代谢

背景情况:

炎症在调节凝血和静血中起着关键作用.
脂蛋白A-IV (ApoA-IV) 具有抗炎和抗血小板特性,但其对凝血的影响尚不清楚.

研究的目的:

阐明ApoA-IV在凝血系统中的作用.
确定ApoA-IV对凝血产生影响的潜在目标和机制.

主要方法:

在使用ELISA的深静脉血栓症 (DVT) 患者的血ApoA-IV水平的量化.
评估ApoA-IV对通过血栓凝结学对凝血的影响.
使用表面等离子体共振和AlphaFold 3进行ApoA-IV相互作用的分析.
在小鼠模型中评估血液静止和血栓形成.

主要成果:

在DVT患者中观察到降低的ApoA-IV水平,与较高的血栓形成风险相关.
ApoA-IV治疗抑制了凝血和血小板聚合,延迟了血块的形成.
ApoA-IV被确定为激活蛋白C (APC) 的激活剂,在特定残留物中相互作用.
动物研究表明,抗ApoA-IV抗体影响了血液静止,而抑制ApoA-IV-APC相互作用的可以抵消ApoA-IV的抗凝固作用.

结论:

ApoA-IV 是凝血和静血的关键调节者,主要是通过增强APC活性.
这项研究增强了对炎症,脂质代谢和血栓形成之间的联系的理解.
这些发现表明,针对ApoA-IV通路的新型抗血栓治疗策略的潜力.

关键词:

激活蛋白C是一种活性蛋白.在阿波利波蛋白A-IV.凝血是凝固的过程.炎症炎症是一种炎症.缺血性中风是因为缺血性中风.

更多相关视频

Ferric Chloride-induced Murine Thrombosis Models

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Intrastriatal Injection of Autologous Blood or Clostridial Collagenase as Murine Models of Intracerebral Hemorrhage

Intrastriatal Injection of Autologous Blood or Clostridial Collagenase as Murine Models of Intracerebral Hemorrhage

Published on: July 3, 2014

相关概念视频

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

Clot Retraction and Fibrinolysis

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

Coagulation

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...

Formation of the Platelet Plug

Formation of the Platelet Plug

The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...